Randomized, double-blind, parallel-group, placebo-controlled,ezetimibe-calibrated, multicenter study evaluating the safety and efficacy of 4 doses and 2 dose-regimens of AVE5530 (4 wks) in patients with mild to moderate hypercholesterolemia

Trial Profile

Randomized, double-blind, parallel-group, placebo-controlled,ezetimibe-calibrated, multicenter study evaluating the safety and efficacy of 4 doses and 2 dose-regimens of AVE5530 (4 wks) in patients with mild to moderate hypercholesterolemia

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Canosimibe; Ezetimibe
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Dec 2008 Ezetimibe identified as an additional treatment arm as reported by ClinicalTrials.gov.
    • 15 Dec 2008 Actual patient number (206) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top